Evidence map›Paper›PMID 40610562›Full record

ArticleScientific reports2025

VISTA is a potential target for immunotherapy in B-cell acute lymphoblastic leukemia in children.

Nourhan K Mohamed, Mohamed A El-Mokhtar, Asmaa M Zahran, Gamal Fadl Mahmoud Gad, Reham Ali Ibrahem

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nourhan K MohamedDepartment of Microbiology and Immunology, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt.
Mohamed A El-MokhtarGilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, P.O. Box 36, Byblos, Lebanon.
Asmaa M ZahranDepartment of Clinical Pathology, South Egypt Cancer Institute, Assiut, University, Assiut, 71515, Egypt.
Gamal Fadl Mahmoud GadDepartment of Microbiology and Immunology, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt.
Reham Ali IbrahemDepartment of Microbiology and Immunology, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt. reham.ali@mu.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoints expressed by immune cells are critical mediators of immune suppression in cancer. Recently, the role of VISTA, an immune checkpoint, in suppressing T cells has been highlighted in several studies. However, its involvement in B-cell acute lymphoblastic leukemia (B-ALL) remains underexplored. In this study, we analyzed the expression of VISTA, the immune-regulatory marker CD244, and its corresponding ligand CD48. Additionally, we examined the expression of the transcription factors FOXD3 and PVRL2 in pediatric patients with B-ALL. Peripheral blood samples from pediatric patients with naïve B-ALL were analyzed using flow cytometry. Additionally, real-time PCR was used to evaluate the downstream regulatory gene FOXD3 expression and the immune regulator PVRL2. VISTA was overexpressed on blasts in B-ALL patients. Also, the frequency of CD3

Indexed as

B7 AntigensImmunotherapyPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolFemaleForkhead Transcription FactorsHumansInfantMaleB7 AntigensForkhead Transcription FactorsVSIR protein, humanB-cell acute lymphoblastic leukemiaCD244CD48FOXD3PVRL2VISTA

Identifiers

PMID40610562
PMCPMC12229706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.